Comparison
11p Partial Monosomy Syndrome C0206115 vs 17 20 Lyase Deficiency Isolated Included CN372394
Clinical comparison between 11p Partial Monosomy Syndrome and 17 20 Lyase Deficiency Isolated Included CN372394 for differential diagnosis and treatment planning.
11p Partial Monosomy Syndrome C0206115
A rare genetic disorder involving deletion of material from chromosome 11. It may result in developmental delays, distinctive facial features, and various medical concerns. Treatment is supportive and individualized based on symptoms.
17 20 Lyase Deficiency Isolated Included CN372394
6 comparison axes
Onset
11p Partial Monosomy Syndrome C0206115
0-0
17 20 Lyase Deficiency Isolated Included CN372394
0-16
Onset patterns differ
Severity
11p Partial Monosomy Syndrome C0206115
severe
17 20 Lyase Deficiency Isolated Included CN372394
severe
Different severity levels
Chronic
11p Partial Monosomy Syndrome C0206115
Chronic
17 20 Lyase Deficiency Isolated Included CN372394
Chronic
Differing course
Communicable
11p Partial Monosomy Syndrome C0206115
No
17 20 Lyase Deficiency Isolated Included CN372394
No
Different transmission
Body System
11p Partial Monosomy Syndrome C0206115
congenital
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
Same/different system
Category
11p Partial Monosomy Syndrome C0206115
genetic
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
Different category
Bottom line
11p-partial-monosomy-syndrome-C0206115 and 17-20-lyase-deficiency-isolated-included-CN372394 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 11p Partial Monosomy Syndrome C0206115 | 17 20 Lyase Deficiency Isolated Included CN372394 | Discriminating power |
|---|---|---|---|
| Developmental and physical pattern | May include congenital developmental delay, distinctive facial features, and varied medical concerns. | A primary chromosomal or dysmorphic phenotype is not established from the supplied data. | High |
| Sex development or puberty | Disordered puberty is not a defining feature in the supplied description. | Impaired sex-steroid production may affect genital development or puberty; exact features are not established here. | Moderate |
| System involvement | Congenital and potentially multisystem presentation from birth. | Endocrine presentation, with onset described from birth through age 16. | Moderate |
When to favor each condition
Choose 11p Partial Monosomy Syndrome C0206115 when
Congenital dysmorphism with developmental concerns
This pattern aligns with a chromosomal deletion rather than an isolated enzyme defect.
High
Confirmed deletion involving 11p
A chromosomal result directly supports partial monosomy over lyase deficiency.
High
Multisystem congenital findings without a steroid diagnosis
The overall pattern favors genetic evaluation for 11p deletion.
Moderate
Choose 17 20 Lyase Deficiency Isolated Included CN372394 when
Suspected disorder of sex development or delayed puberty
An endocrine steroidogenic disorder should be considered and specialist-confirmed.
Moderate
Steroid results suggest impaired 17,20-lyase activity
This biochemical pattern is more relevant than chromosomal deletion, but cutoffs are not supplied.
Moderate
Normal chromosomal testing with endocrine-predominant illness
This makes 11p partial monosomy less likely.
Moderate
How key tests differ
| Test | 11p Partial Monosomy Syndrome C0206115 | 17 20 Lyase Deficiency Isolated Included CN372394 | Interpretation |
|---|---|---|---|
| Karyotype or chromosomal microarray | Deletion of material from chromosome 11 may be identified. | No specific chromosomal abnormality is established. | A confirmed 11p deletion supports the left diagnosis; normal testing does not by itself prove the right diagnosis. |
| Steroid hormone profile | No characteristic steroid pattern is supplied. | Sex-steroid production may be reduced; exact thresholds are not established here. | Abnormal results require endocrine interpretation and do not alone confirm isolated lyase deficiency. |
| Targeted genetic testing | Chromosomal analysis is the relevant genetic test. | CYP17A1-related testing may be considered after clinical correlation. | Gene selection and variant interpretation belong to a specialist; a result is not supplied here. |
Prognosis comparison
11p Partial Monosomy Syndrome C0206115
- Outcome
- Often substantial lifelong developmental and medical needs, but individual prognosis is variable and not quantified here.
- Factors
- Deletion extent, involved genes, associated anomalies, and available supportive care.
17 20 Lyase Deficiency Isolated Included CN372394
- Outcome
- Outcome depends on the degree of hormone deficiency and associated features; mortality is not established.
- Factors
- Enzyme impairment, chromosomal sex, puberty management, and any confirmed adrenal involvement.
Time frame: Both are chronic; features may be congenital or become apparent by adolescence.
Accurate diagnosis, specialist follow-up, and individualized care are central.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental disability | Developmental delay may be an important feature. Developmental disability is not established from the supplied data. Severity and outcome vary and should not be assumed. |
| Pubertal or reproductive effects | Not identified as defining in the supplied description. Sex-hormone deficiency may affect puberty or fertility, but specifics are not established. Assessment should be individualized by endocrinology. |
| Associated medical complexity | Various congenital medical concerns may require coordinated care. Potential adrenal or other endocrine involvement is not established for the isolated form here. Neither condition is communicable; both are described as chronic and severe. |
Patient education highlights
- HighDifferent causes
One condition results from missing chromosome 11 material; the other concerns steroid hormone production. They are not interchangeable.
- HighSpecialist interpretation
Genetic and hormone results can be abnormal findings without proving a diagnosis. Ask a clinician to explain them.
- MediumIndividualized care
Management is supportive or endocrine and tailored to findings. No treatment dose can be inferred from this comparison.